Advances in soluble guanylate cyclase stimulator

HU Liqing; YI Rui; LI Qianbin

doi:10.11665/j.issn.1000-5048.20160504

Journal of China Pharmaceutical University > 2016 > 47(5): 531-536. > DOI: 10.11665/j.issn.1000-5048.20160504

HU Liqing, YI Rui, LI Qianbin. Advances in soluble guanylate cyclase stimulator[J]. Journal of China Pharmaceutical University, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504

Citation:

HU Liqing, YI Rui, LI Qianbin. Advances in soluble guanylate cyclase stimulator[J]. Journal of China Pharmaceutical University, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504

Citation:

HU Liqing, YI Rui, LI Qianbin. Advances in soluble guanylate cyclase stimulator[J]. Journal of China Pharmaceutical University, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504

PDF (1264 KB)

Advances in soluble guanylate cyclase stimulator

More Information

Graphical Abstract

Abstract

Abstract

Soluble guanylate cyclase is a key signal transduction enzyme in the body, which can activate the NO-sGC-cGMP signaling pathway and inhibit the TGF-β signaling pathway. cGMP is one of the most important second messengers and also involved in a series of physiological or pathological responses including vasodilation, inhibition of platelet aggregation, inhibition of cell proliferation and so on. When TGF-β signaling pathway is inhibited, it can inhibit issue fibrosis and cell proliferation. Recent studies have shown that sGC can be activated directly to treat a variety of diseases. As a new class of potential drugs, sGC stimulators have shown many unique advantages. Herein, the mechanism and the latest research progress of sGC stimulators are reviewed, which could provide a useful information for further research of sGC stimulators.
- soluble guanylate cyclase(sGC),
- sGC stimulators,
- mechanism of action,
- signaling pathway,
- riociguat

FullText(HTML)

References (31)

References

[1]	Derbyshire ER,Marletta MA.Structure and regulation of soluble guanylate cyclase[J].Ann Rev Biochem,2012,81:533-559.
[2]	Wang-Rosenke Y,Neumayer HH,Peters H.NO signaling through cGMP in renal tissue fibrosis and beyond:key pathway and novel therapeutic target[J].Curr Med Chem,2008,15:1396-1406.
[3]	Stasch JP,Pacher P,Evgenov OV.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease[J].Circulation,2011,123(20):2263-2273.
[4]	Stasch JP,Schlossmann J,Hocher B.Renal effects of soluble guanylate cyclase stimulators and activators:a review of the preclinical evidence[J].Curr Opin Pharmacol,2015,21:95-104.
[5]	Kotzki S,Roustit M,Arnaud C,et al.Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats[J].J Pharmacol Exp Ther,2013,346(3):424-431.
[6]	Friebe A, Koesling D. The function of NO-sensitive guanylyl cyclase:what we can learn from genetic mouse models[J].Nitric Oxide,2009,21(3/4):149-156.
[7]	Hill BG,Dranka BP,Bailey SM,et al.What part of NO don′t you understand? Some answers to the cardinal questions in nitric oxide biology[J].J Biol Chem,2010,285(26):19699-19704.
[8]	Castro NE,Kato M,Park JT,et al.Transforming growth factor β1(TGF-β1)enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells[J].J Biol Chem,2014,289(42):29001-29013.
[9]	Seferian A,Simonneau G.Therapies for pulmonary arterial hypertension:where are we today,where do we go tomorrow[J]?Eur Respir Rev,2013,22(129):217-226.
[10]	Crosswhite P,Sun Z.Nitric oxide,oxidative stress and inflammation in pulmonary arterial hypertension[J].Hypertens,2010,28(2):201-212.
[11]	Baldi F,Fuso L,Arrighi E,et al.Optimal management of pulmonary arterial hypertension prognostic indicators to determine treatment course[J].Ther Clin Risk Manag,2014,10:825-839.
[12]	Liu Y.Renal fibrosis:new insights into the pathogenesis and therapeutics[J].Kidney Int,2006,69(2):213-217.
[13]	Judd E, Calhoun DA. Management of hypertension in CKD:beyond the guidelines[J].Adv Chronic Kidney Dis,2015,22(2):116-122.
[14]	Geschka S,Kretschmer A,Sharkovska Y,et al.Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats[J].PLoS One,2011,6(7):e21853.
[15]	Gabrielli A,Avvedimento EV,Krieg T.Scleroderma[J].N Engl J Med,2009,360(19):1989-2003.
[16]	Beyer C,Distler O,Distler JH.Innovative antifibrotic therapies in systemic sclerosis[J].Curr Opin Rheumatol,2012,24(3):274-280.
[17]	Beyer C,Zenzmaier C,Palumbo-Zerr K,et al.Stimulation of the soluble guanylate cyclase(sGC)inhibits fibrosis by blocking non-canonical TGFβ signalling[J].Ann Rheum Dis,2015,74(7):1408-1416.
[18]	Stasch JP,Hobbs AJ.NO-independent,haem-dependent soluble guanylate cyclase stimulators[J].Handb Exp Pharmacol,2009(191):277-308.
[19]	Yasuda Y,Arakawa T,Nawata Y,et al.Design,synthesis,and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor(HIF)-1 inhibitors[J].Bioorg Med Chem,2015,23(8):1776-1787.
[20]	Luo ZY,Jiang JT,Qin XH.The advancement in YC-1 anti-hepatocellular carcinoma mechanisms[J].Med Recapit,2011,17:2288-2290.
[21]	Chen YF,Lin YC,Chen JP,et al. Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents[J].Bioorg Med Chem Lett,2015,25(18):3873-3877.
[22]	Xiao J,Jin C,Liu Z,et al.The design,synthesis,and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents[J].Org Biomol Chem,2015,13(26):7257-7264.
[23]	Soeiro-Pereira PV,Falcai A,Kubo CA,et al.BAY 41-2272 activates host defence against local and disseminated Candida albicans infections[J].Mem Inst Oswaldo Cruz,2015,110(1):75-78.
[24]	Badejo AM Jr,Nossaman VE,Pankey EA,et al.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator,BAY 41-8543,are modulated by nitric oxide[J].Am J Physiol Heart Circ Physiol,2010,299(4):H1153-H1159.
[25]	Watts JA,Gellar MA,Fulkerson MB,et al.A soluble guanylate cyclase stimulator,BAY 41-8543,preserves right ventricular function in experimental pulmonary embolism[J].Pulm Pharmacol Ther,2013,26(2):205-211.
[26]	Hoffmann LS,Etzrodt J,Willkomm L,et al.Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue[J].Nat Commun,2015,6:7235.
[27]	Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat(BAY 63-2521):a potent,oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension[J].ChemMedChem,2009,4(5):853-865.
[28]	Lang M,Kojonazarov B,Weissmann N,et al.The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats[J].PLoS One,2012,7(8):e43433.
[29]	Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators inpulmonary hypertension[J].Handb Exp Pharmacol,2013,218:279-313.
[30]	Ghofrani HA,Galiè N,Grimminger F,et al.Riociguat for the treatment of pulmonary arterial hypertension[J].N Engl J Med,2013,369(4):330-340.
[31]	Dees C,Beyer C,Distler A,et al.Stimulators of soluble guanylate cyclase(sGC)inhibit experimental skin fibrosis of different aetiologies[J].Ann Rheum Dis,2015,74(8):1621-1625.

Cited By

Get Citation

PDF

XML

Article views (1344) PDF downloads (5641)

Turn off MathJax

Article Contents

Abstract

References

Advances in soluble guanylate cyclase stimulator

Abstract

References

Catalog

Export File

Citation

Format

Content